TLR Antagonists for Hypercholesterolemia via Immune Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current strategies for selectively inhibiting Toll-Like Receptor (TLR) activity do not effectively address the regulation of blood cholesterol and lipid concentrations, which are associated with various diseases such as hypercholesterolemia and hyperlipidemia.
Innovation Solution
Inhibiting TLR signaling pathways by administering TLR antagonist compounds, such as small molecules, antibodies, or synthetic oligonucleotides, to mammals with elevated blood cholesterol and lipid levels, targeting proteins like MyD88, IRAK, and NF-κB, to lower blood cholesterol and lipid concentrations and increase the HDL-C to LDL-C ratio.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If TLR antagonist compounds are administered to inhibit TLR signaling, then blood cholesterol and lipid levels are lowered, but the mechanism by which immune response modulation affects metabolic parameters was previously unknown
Solution Approach 1:
The patent establishes a feedback mechanism where TLR signaling inhibition leads to reduced inflammatory response, which in turn lowers blood cholesterol and lipid levels. The discovery that TLR pathway activation influences metabolic parameters creates a feedback loop between immune response and lipid metabolism, allowing for therapeutic intervention in hypercholesterolemia through immune modulation.
2Quantity of substance
If conventional lipid-lowering strategies are used, then blood cholesterol levels are reduced, but they do not address the underlying inflammatory and immune pathways involved in hypercholesterolemia
Solution Approach 1:
The patent demonstrates that TLR antagonist compounds have multiple functions: they inhibit inflammatory responses, modulate immune system activity, and simultaneously lower blood cholesterol and lipid levels. This multi-functionality allows a single therapeutic approach to address both the inflammatory component and the metabolic parameter of hypercholesterolemia, making the treatment more versatile than conventional lipid-lowering agents.
3Reliability
If TLR signaling is inhibited to treat hypercholesterolemia, then disease risk is reduced, but the connection between innate immune response and lipid metabolism was previously unrecognized
Solution Approach 1:
The patent identifies TLR signaling as an intermediary mechanism that connects the innate immune response to lipid metabolism. By inhibiting TLR signaling, the patent interrupts the pathway through which inflammatory responses influence blood cholesterol and lipid levels, thereby providing disease protection while revealing the previously unrecognized connection between immune activation and metabolic dysfunction.
Data Source
AI summary
The invention provides the use of TLR inhibitors or a pharmaceutically acceptable derivative thereof, optionally in combination with one or more lipid lowering composition, cholesterol lowering composition, diuretics, non-steroidal anti-inflammatory compounds (NSAIDs), antibodies, antisense oligonucleotides, TLR agonists, TLR antagonists, peptides, proteins or gene therapy vectors or combinations thereof for the prevention or treatment of hypercholesterolemia and/or hyperlipidemia and/or diseases associated therewith.